|
DiagnoCure Is Focused On High-Value Molecular Markers For Cancer Diagnostics, Allowing Physicians To Answer Key Questions In Managing Patients With Cancer |
|
|
DiagnoCure Inc. (CUR-TSX) |
|
|
“With Previstage GCC, we measure 50% of each lymph nodes resected during the surgery, and amplify the GCC signal with molecular technology. With this method, we can find one cancer cell in ten million normal cells. The pathologist can find one cancer cell in about two hundred normal cells. Therefore, this test is about 100,000 times more sensitive than looking under a microscope, and we think we can find the 30% of patients that were missed by the traditional method” - John C. Schafer (CUR) (Interview published July 11, 2008) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
Become a member and access our interview with: John C. Schafer, CEO (CUR)
|
|
